NEWS & PRESENTATIONS

News & Press Releases - 2017

November 30, 2017

Incysus Announces Appointment of Siraj Ali, MD, PhD to its Scientific Advisory Board

Incysus announced the addition of Siraj Ali, MD, PhD to its Scientific Advisory Board (SAB).  Dr. Ali is a physician-scientist and leads translational research efforts at Foundation Medicine.  He focuses on identifying predictive biomarkers for targeted anti-neoplastic and cancer immunotherapies, which encompasses both basic cancer biology and exceptional responders in the clinic.

October 17, 2017

Incysus Announces FDA Clearance of IND Application for a Phase I Study of a Gamma-Delta (γδ) T Cell Leukemia and Lymphoma Immunotherapy

Incysus announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) allowing the initiation of a Phase I clinical trial testing the allogeneic delivery of expanded and activated gamma-delta (γδ) T cells for the treatment of patients with blood cancers following haploidentical stem cell transplantation.

October 12, 2017

CHEMO-PROOF T CELLS - By Lauren Martz, Senior Writer, BioCentury

Incysus and our innovative technology were profiled in the October 12, 2017 edition of BioCentury Innovations.

September 19, 2017

Incysus Submits Investigational New Drug (IND) Application for Allogeneic Gamma-Delta T Cell Immunotherapy for Leukemia and Lymphoma

Incysus today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a first-ever Phase I study of expanded and activated gamma-delta (γδ) T cells for the treatment of patients with blood cancers following haploidentical stem cell transplantation.

September 7, 2017

Incysus Collaborators Publish Review in Bone Marrow Transplantation

Incysus' scientific co-founder Dr. Lawrence S. Lamb, PhD and collaborator Dr. Ayman Saad, MD at the University of Alabama at Birmingham (UAB) published in print a review of current and emerging strategies of T cell depletion in allogeneic hematopoietic stem cell transplantation in the journal Bone Marrow Transplantation (www.nature.com/bmt), (2017) 52, 1241-1248.

August 24, 2017

Incysus Announces Formation of Scientific Advisory Board

Incysus announces the formation of its inaugural Scientific Advisory Board (SAB) with a world-leading group of experts in the areas of immunology, cell therapy and oncology.

August 23, 2017

Incysus Scientific Co-Founder to Present at Immuno-Oncology Summit

Incysus' collaborator and scientific co-founder, Dr. Lawrence S. Lamb, MN, PhD from the University of Alabama at Birmingham (UAB), will be presenting at the Immuno-Oncology Summit in Boston on Wednesday, August 30th, 2017 (http://immuno-oncologysummit.com/T-Cell/).

May 4, 2017

UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors

The University of Alabama at Birmingham (UAB), Emory University and Children's Healthcare of Atlanta have licensed technology to Incysus to develop a novel cellular therapy called Drug-Resistant Immunotherapy or DRI.

April 12, 2017

Incysus Granted European Patent Covering its Drug Resistant Immunotherapy (DRI) Technology 

The European Patent Office granted EU Patent No. 2496244 covering claims related to methods of combining chemotherapy with immunotherapy.

March 24, 2017

Incysus Announces Preclinical Data Presentations of γδ T Cell Immunotherapy Programs at Upcoming Medical Conferences

Incysus' academic collaborators present preclinical data highlighting their γδ T cell immunotherapy programs at major medical conferences.

©2020 by Incysus Therapeutics, Inc.  |  info@incysus.com  |  Privacy Policy  |  Terms of Use